A vs ACGL Stock Comparison

Scores Breakdown

Metric	A	ACGL
📈 Growth	26/30	16/30
💰 Profitability	17/20	17/20
🏦 Financial Health	15/20	18/20
💵 Valuation	16/20	14/20
⚠️ Risk (lower is better)	5/10	4/10
Overall Score	79/100	71/100

Side-by-Side Summaries

A Analysis	ACGL Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory From 2024 Q3 to 2026 Q2, Revenues remained in a tight band around $4.47–$5.21B, finishing at $4.67B in 2026 Q2 (slightly below the start). The eight-quarter path shows a trough in 2025 Q3 (~~$4.51B) and a peak in 2025 Q2 (~~$5.21B), signaling modest top-line volatility rather than sustained growth. Conversely, Net Income Attributable To Parent rose from about $886M in 2024 Q3 to $1.057B in 2026 Q2, reflecting improving profitability despite revenue fluctuations. Net income growth (~+19%) over the period supports a cautious positive trajectory. 💰 Margins & Cash Flow Operating margins have been solid, frequently in the mid-20s to low-30s range (examples: 2025 Q1 ~30%, 2025 Q3 ~34%, 2024 Q4 ~14–21% depending on quarter’s mix). This indicates healthy operating leverage when revenue spikes occur. Cash flow shows robust operating activity: Net Cash Flow From Operating Activities generally around $1.1–$2.2B per quarter (e.g., 2026 Q2 ~$1.32B, 2025 Q4 ~$2.19B). Investing activities are routinely negative, with ongoing cash used for growth, while financing activity varies by quarter. Overall, cash generation supports ongoing liquidity and shareholder value. 🛡️ Balance Sheet & Liquidity Balance sheets exhibit solid liquidity and limited noncurrent leverage. Across quarters, current assets exceed current liabilities (e.g., 2026 Q2: $85.18B vs. $61.15B current liabilities), yielding a healthy current ratio (~1.4). Noncurrent liabilities are effectively zero, and equity attributable to parent sits around $24.0–$24.2B, implying durable solvency and resilience against near-term shocks. ⚠️ Key Drivers & Risks Drivers: Insurance underwriting performance, pricing discipline, and favorable catastrophe experience can sustain margins and earnings; strong capital markets support reinsurance activities. Risks: Catastrophe losses, regulatory changes, and revenue cyclicality can pressure margins and cash flows; valuation sensitivity to premiums/rates and reserve development.

A Analysis

ACGL Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

From 2024 Q3 to 2026 Q2, Revenues remained in a tight band around $4.47–$5.21B, finishing at $4.67B in 2026 Q2 (slightly below the start). The eight-quarter path shows a trough in 2025 Q3 (~~$4.51B) and a peak in 2025 Q2 (~~$5.21B), signaling modest top-line volatility rather than sustained growth. Conversely, Net Income Attributable To Parent rose from about $886M in 2024 Q3 to $1.057B in 2026 Q2, reflecting improving profitability despite revenue fluctuations. Net income growth (~+19%) over the period supports a cautious positive trajectory.

💰 Margins & Cash Flow

Operating margins have been solid, frequently in the mid-20s to low-30s range (examples: 2025 Q1 ~30%, 2025 Q3 ~34%, 2024 Q4 ~14–21% depending on quarter’s mix). This indicates healthy operating leverage when revenue spikes occur. Cash flow shows robust operating activity: Net Cash Flow From Operating Activities generally around $1.1–$2.2B per quarter (e.g., 2026 Q2 ~$1.32B, 2025 Q4 ~$2.19B). Investing activities are routinely negative, with ongoing cash used for growth, while financing activity varies by quarter. Overall, cash generation supports ongoing liquidity and shareholder value.

🛡️ Balance Sheet & Liquidity

Balance sheets exhibit solid liquidity and limited noncurrent leverage. Across quarters, current assets exceed current liabilities (e.g., 2026 Q2: $85.18B vs. $61.15B current liabilities), yielding a healthy current ratio (~1.4). Noncurrent liabilities are effectively zero, and equity attributable to parent sits around $24.0–$24.2B, implying durable solvency and resilience against near-term shocks.

⚠️ Key Drivers & Risks

Drivers: Insurance underwriting performance, pricing discipline, and favorable catastrophe experience can sustain margins and earnings; strong capital markets support reinsurance activities.
Risks: Catastrophe losses, regulatory changes, and revenue cyclicality can pressure margins and cash flows; valuation sensitivity to premiums/rates and reserve development.

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 74

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"